Transplantation of HLA-mismatched stem cells may allow determination of chimerism status of single cells by differential expression of HLA molecules. Monoclonal antibodies against HLA antigens can be used to determine the HLA type of sub-populations by standard flow cytometry. Blood samples from 23 patients transplanted from HLA-mismatched family donors were monitored using HLA-specific antibodies. Suitable antibodies could be found for all donor recipient pairs by using differences in HLA Bw4 and Bw6 groups or other serological antigens. Pretransplant controls of donor and recipient were used to correct for variable fluorescence intensities of the antibodies and sub-populations. Owing to the high sensitivity, cell populations with a minimum frequency of 0.1% were detectable. Flow-cytometric analysis was confirmed by chimerism analysis of immunomagnetically isolated T cells by standard PCR technique. In addition to chimerism evaluation, HLA antibodies improved the detection of leukemic cells after transplantation with aberrant phenotype. In conclusion, flow cytometry using antibodies against HLA antigens is an interesting tool for determination of chimerism and minimal residual disease after HLA-mismatched transplantation. Information about the chimerism status is given on a single-cell level and allows fast and convenient analysis of sub-populations.
Introduction
HLA-mismatched transplantation has become a realistic option for patients lacking an HLA-identical donor. Sources of stem cells are peripheral blood stem cells, bone marrow or cord blood cells. Special conditioning regimens in combination with profound T cell depletion of the stem cell grafts allow fast engraftment with low rates of graft-versus-host disease and transplant related mortality. [1] [2] [3] In addition, cord blood stem cells differing at one or two major antigens may also be used for HLA-mismatched transplantation, either as a single graft or combining several cord bloods into one graft. [4] [5] [6] Owing to the strong HLA disparity, rejection may occur more frequently than in the HLA identical setting. Frequent and sensitive monitoring of T cell chimerism after transplantation is important to enable early diagnosis and effective management of pending graft rejection.
On the other hand, differences in HLA antigens offer the possibility of differentiating donor and recipient cells by these antigens. In contrast to minor antigens, major histocompatibility antigens can be distinguished by monoclonal antibodies thus providing a powerful tool for monitoring chimerism by a simple flow-cytometric analysis. Antisera and monoclonal antibodies have been used extensively for determination of chimerism in animal models of allogeneic transplantation. Mainly differences in CD45 (45.1 and 45.2) or Thy 1 (Thy 1.1 and Thy1.2) were used, but also antibodies against H-2 have been described. [7] [8] [9] [10] The standard techniques for determining chimerism in humans are fluorescence in situ hybridization (FISH) of sex chromosomes [11] [12] [13] [14] or PCR of long terminal repeats. [15] [16] [17] These methods allow sensitive detection of the chimeric proportion of the cells, but give no information on a single cell level. Here, we show that monoclonal-antibodies to HLA antigens allow determination of chimerism in human haploidentical allogeneic hematopoietic stem cell transplantation with the possibility to trace single cells in combination with distinct lineage markers within hours with high accuracy and sensitivity.
Materials and methods
Peripheral blood from 23 patients transplanted from HLAmismatched family donors were monitored for autologous cells using HLA-specific antibodies in combination with lineage specific antibodies. Informed consent forms were signed by all subjects and the study was approved by the ethical committee of the University of Tuebingen. Patients' characteristics and antibodies for analysis are given in Table 1 .
Antibodies FITC-labelled and biotinylated antibodies (one-lambda, Canoga Park, CA, USA) were available for the following HLA-serotypes: A2/28, A3, A9, B7/27, B8, B12, B27 and Bw4 or Bw6 could be used also for detection of split antigens. Differential expression of HLA molecules on donor and recipient was confirmed in pretransplant controls.
Flow cytometry
The staining and analysis followed standard flow cytometry procedures. Briefly, 100 ml of whole blood was incubated for 20 min with 20 ml of monoclonal antibodies each, lysed with 4 ml of lysing buffer (FACSLyse (Becton Dickinson Immunocytometry System, BDIS, San Jose, CA, USA)) for 6 min, centrifuged at 400 g for 7 min and washed again with 4 ml of buffer (FACSFlow, BDIS). Cells were then analyzed on a FACSCalibur flow cytometer (BDIS) using Cellquest software. Gates were set on lymphocytes and cells of interest, like CD5 þ , CD3 þ and CD56 þ . The percentage of stained and unstained cells was determined thereafter.
Chimerism analysis
Detection of chimerism by PCR was performed on immunomagnetically isolated T cells. Briefly, peripheral blood cells were incubated with CD3-labelled beads (Dynal, Oslo, Norway) for 30 min. Cells were then exposed to a magnetic field and unbound cells were washed out. Positively selected cells were analyzed by PCR as described previously. 18 
Results
Fluorescence intensity of leukocyte sub-populations Fluorescence intensity differed between sub-populations. Granulocytes had about 1 log lower fluorescence intensity than monocytes and lymphocytes. Therefore, only corresponding sub-populations were compared with their fluorescence intensity ( Figure 1 ). Table 1 and Figure 2 give an example of how the diagnostic antibodies were selected. The patient had the phenotype Following T cell chimerism after haploidentical transplantation Twenty-four patients were analyzed after transplantation for T cell recovery and T cell chimerism in peripheral blood. Fluorescence intensity of HLA antibodies against the same HLA-antigen differed among patients. Therefore, both donor and recipient pretransplant samples were analyzed for baseline fluorescence levels. Post-transplant samples fluorescence intensity is then compared with the baseline levels ( Table 1) . In all but one case, HLA differences and antibodies could be found to distinguish between donor and recipient as described above. For one patient, biotin-labelled A3 antibody was used, as an FITC-labelled antibody was not available. In one patient, analysis was not possible because fluorescence intensity between donor and recipient cells was too low, despite a difference in HLA Bw4 as determined by molecular HLA typing. Mixed chimerism could be detected in 15 patients. Analysis was confirmed by standard PCR technique at several time points. Complete chimerism could be achieved in 14 patients by immunological intervention (i.e. withdrawal of immunosuppression or donation of donor T cells). Graft rejection was observed in three patients, and in two patients a second transplantation was successful.
Selection of appropriate antibody
Following mixed lineage chimerism after haploidentical transplantation Mixed lineage chimerism could be detected in a patient with severe combined immunodeficiency (SCID), 3 years after haploidentical transplantation from her mother. The patient was transplanted without conditioning so that all lineages (except T cells) could theoretically arise from both donor and recipient. Although T and NK cells were completely of donors type (B12 þ ), B cells were still mainly of recipient type (B12À). Granulocytes and monocytes consisted mainly of recipient cells with a small proportion of donor cells (Figure 3) . Monitoring immunological intervention after transplantation HLA antibodies can be used to follow closely the effects of immunological interventions in patients undergoing haploidentical transplantation. An example is shown in Figure 4 . Initially, T cells reappearing after graft-versushost prophylaxis with OKT3 from day À8 to day 17 were of donor type. Residual autologous T cells were found with 6% on day 22 increasing steadily to 68% on day 39. After withdrawal of mycophenolate mofetil (MMF) on day 39 and donation of 25 Â 10 6 CD3 þ /kg donor lymphocytes on day 42, autologous cells vanished almost completely within 3 weeks and donor cells reappeared. On day 110, autologous cells increased again to over 80%. Again, three doses of donor leukocyte infusions (DLI) with 25 Â 10 6 CD3 þ donor T cells per kg were given, leading to a decrease in autologous CD3 þ cells to less than 5% (Figure 4) . Determination of chimerism by flow cytometry could be confirmed by conventional PCR analysis of immunomagnetically isolated T cells, which was performed in parallel. Note that data points in the PCR curve represent ranges (o1, 1-5, 5-10,y.) while flow-cytometry data allows very accurate chimerism determination.
Improved detection of minimal residual disease after transplantation HLA antibodies can also be used for monitoring the number of residual tumour cells in peripheral blood and marrow after transplantation. HLA antibodies were used to confirm the detection of leukemic cells presenting an aberrant phenotype, or if an aberrant phenotype was missing. Figure 5 shows peripheral blood of a patient with CD33 þ AML after haploidentical transplantation in 
Discussion
Monitoring chimerism after allogeneic transplantation has become a diagnostic standard. Monitoring of chimerism is of significant therapeutic value, as increasing numbers of autologous cells may indicate graft rejection or leukemic relapse. 19 Several techniques for monitoring chimerism have been described: in sex mismatched transplantation, Y chromosomes can be detected in metaphase analysis or FISH.
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PCR techniques based on the detection of short tandem repeats (STR) has become the standard technique in many centers as it can also be used in sex-matched hematopoietic stem cell transplantation. 18 Both techniques yield sensitive and reproducible results, but are time consuming and cannot distinguish between sub-populations. In part, this can be overcome by separating sub-populations before analysis, 20, 21 or performing surface staining in combination with FISH, 22, 23 but this again increases sample size and working time.
Monoclonal antibodies against human MHC antigens are rare and mainly of the IgM subclass, probably because these were preferred for HLA typing in cytotoxicity assays. However, IgM monoclonal antibodies are difficult to label with fluorescent dyes leading to restricted availability of directly conjugated mAbs. Only a few IgG antibodies are available commercially, but they were sufficient to cover almost 90% of our donor-recipient pairs. Antibodies against Bw4 and Bw6 could be used in the case that these group alleles differed; antibodies against split and broad antigens (i.e. A9) were able to detect all split antigens (i.e. A9, A23 and A24).
HLA-mismatched transplantation has become a realistic option if a HLA-matched donor is not available. Severe graft-versus-host disease can be managed by T cell depletion techniques and the source can be peripheral stem cells as well as cord blood cells. However, due to the strong activation of donor T cells by HLA-mismatched cells, special efforts have to be undertaken to prevent graft rejection. Early protocols therefore use large amounts of highly purified stem cells (megadose concept) and highintensity conditioning regimen. [24] [25] [26] More recently, protocols using T and B cell-depleted grafts and reduced intensity conditioning regimens allowed successful haploidentical hematopoietic stem cell transplantation with a low incidence of infections and transplant-related mortality. 1, 27 However, reduced conditioning regimens may be less effective in eradication of host T cells, hence monitoring of residual T cells of host origin is mandatory. In the early post-transplant phase, T cells do not contribute substantially to the RNA content of a blood sample and might therefore not be detected with standard PCR techniques. However, flow cytometry is able to detect even single T cells with high accuracy and allows monitoring chimerism on a daily basis. We were able to detect routinely T cells below 1 cell/ml by using only 2 ml of peripheral blood. Close monitoring of chimerism allows prevention of pending graft rejection with modest interventions like cessation of immunosuppressive drugs, infusion of low amounts of donor T cells or stem cell boosts.
Detection of minimal residual disease is normally performed by cytogenetic analysis or PCR of known leukemic sequences. PCR techniques are sensitive but need special primers that are not available in all cases. 28 In the last few years, flow cytometric methods have been developed using multicolour staining of cells and detecting leukemic blasts by their aberrant phenotype. 29, 30 These techniques are fast and highly sensitive, but require a sophisticated evaluation and determination of the individual aberrant leukemic phenotype. Here, the use of HLA antibodies might improve the detection of leukemic cells and confirm the analysis.
The use of HLA antibodies for monitoring chimerism and minimal residual disease after HLA-mismatched transplantation can be performed in any standard flow cytometry lab and does not need special equipment. Pretransplant samples of donor and recipient are mandantory to take into account varying fluorescence intensity between individuals. Combining HLA antibodies with lineage markers may improve our knowledge of the regenerating haematopoiesis after allogeneic transplantation and enable effective and precise control of the patients' immune system. This method can easily be added to standard flow cytometric protocols and may extend the diagnostic capabilities and make therapeutic interventions more precise.
